Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.

Trial Details

NCT ID
NCT06162377
Phase
PHASE4
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Methylnaltrexone
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • 18 years of age or older. Because no dosing or adverse event data are currently available on the use of methylnaltrexone in participants \<18 years…
  • Histologically-confirmed oral cavity squamous cell carcinoma \[(T1-T4, N (any)\] that is amenable to curative-intent surgery
  • Able to receive the study drug for at least two weeks preoperatively
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →